Gary Tong
About
Gary Tong is a scholar working on Physiology, Molecular Biology and Pharmacology.
According to data from OpenAlex, Gary Tong has authored 35 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Physiology, 10 papers in Molecular Biology and 9 papers in Pharmacology. Recurrent topics in Gary Tong's work include Alzheimer's disease research and treatments (9 papers), Cholinesterase and Neurodegenerative Diseases (8 papers) and Neuroscience and Neuropharmacology Research (6 papers). Gary Tong is often cited by papers focused on Alzheimer's disease research and treatments (9 papers), Cholinesterase and Neurodegenerative Diseases (8 papers) and Neuroscience and Neuropharmacology Research (6 papers). Gary Tong collaborates with scholars based in United States, Germany and United Kingdom. Gary Tong's co-authors include Jeffrey L. Cummings, Clive Ballard, Stuart A. Lipton, Dongxian Zhang, Maria Talantova, Peng Xia, Nobuki Nakanishi, Yeonsook Shin, Shichun Tu and Dongdong Yao and has published in prestigious journals such as Nature Medicine, Neuron and Journal of Neuroscience.
In The Last Decade
Gary Tong
32 papers receiving 2.1k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Gary Tong United States | 19 | 862 | 802 | 662 | 354 | 324 | 35 | 2.1k | ||
| Nobuya Matsuoka Japan | 32 | 722 0.8× | 1.1k 1.4× | 826 1.2× | 374 1.1× | 449 1.4× | 96 | 2.9k | ||
| Per‐Göran Gillberg Sweden | 31 | 885 1.0× | 704 0.9× | 649 1.0× | 318 0.9× | 229 0.7× | 79 | 2.6k | ||
| Eleanor Drummond Australia | 22 | 1.3k 1.5× | 868 1.1× | 385 0.6× | 196 0.6× | 338 1.0× | 55 | 2.2k | ||
| Nicola Origlia Italy | 30 | 718 0.8× | 702 0.9× | 642 1.0× | 181 0.5× | 249 0.8× | 60 | 2.3k | ||
| Francisco J. Gil‐Bea Spain | 31 | 833 1.0× | 831 1.0× | 662 1.0× | 212 0.6× | 406 1.3× | 53 | 2.5k | ||
| Paul Ardayfio United States | 14 | 920 1.1× | 391 0.5× | 359 0.5× | 452 1.3× | 336 1.0× | 33 | 1.7k | ||
| Karen H. Gylys United States | 28 | 1.7k 2.0× | 1.0k 1.3× | 800 1.2× | 248 0.7× | 449 1.4× | 60 | 2.6k | ||
| Emma L. Jones United Kingdom | 7 | 929 1.1× | 604 0.8× | 228 0.3× | 353 1.0× | 324 1.0× | 10 | 2.0k | ||
| Hitoshi Tanimukai Japan | 18 | 1.2k 1.4× | 991 1.2× | 446 0.7× | 164 0.5× | 353 1.1× | 55 | 2.3k |
Countries citing papers authored by Gary Tong
Since
Specialization
Citations
This map shows the geographic impact of Gary Tong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary Tong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary Tong more than expected).
Fields of papers citing papers by Gary Tong
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Gary Tong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary Tong. The network helps show where Gary Tong may publish in the future.
Co-authorship network of co-authors of Gary Tong
This figure shows the co-authorship network connecting the top 25 collaborators of Gary Tong. A scholar is included among the top collaborators of Gary Tong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gary Tong. Gary Tong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Grossberg, George T., Gary Tong, Anna Burke, & Pierre N. Tariot. (2019). Present Algorithms and Future Treatments for Alzheimer’s Disease. Journal of Alzheimer s Disease. 67(4). 1157–1171.
2.
Cummings, Jeffrey L., Gary Tong, & Clive Ballard. (2019). Treatment Combinations for Alzheimer’s Disease: Current and Future Pharmacotherapy Options. Journal of Alzheimer s Disease. 67(3). 779–794.
3.
Atri, Alireza, Gary Tong, Jouko Isojärvi, & Tomas Odergren. (2016). A 5-HT6 Antagonist as Adjunctive Therapy to Cholinesterase Inhibitors in Patients with Mild-to-Moderate Alzheimer's Disease: Idalopirdine in Phase III. American Journal of Geriatric Psychiatry. 24(3). S147–S148.
4.
Takahashi, Hiroto, Peng Xia, Jiankun Cui, et al.. (2015). Pharmacologically targeted NMDA receptor antagonism by NitroMemantine for cerebrovascular disease. Scientific Reports. 5(1). 14781–14781.
5.
Tong, Gary, Junsheng Wang, Oleksandr Sverdlov, et al.. (2012). Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study of the Oral γ-Secretase Inhibitor BMS-708163 (Avagacestat): Tolerability Profile, Pharmacokinetic Parameters, and Pharmacodynamic Markers. Clinical Therapeutics. 34(3). 654–667.
6.
Tong, Gary, Junsheng Wang, Oleksandr Sverdlov, et al.. (2012). Effects of Single Doses of Avagacestat (BMS-708163) on Cerebrospinal Fluid Aβ Levels in Healthy Young Men. Clinical Drug Investigation. 32(11). 761–769.
7.
Dockens, Randy, Junsheng Wang, Oleksandr Sverdlov, et al.. (2012). A Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Avagacestat (BMS-708163) in Healthy Young and Elderly Subjects. Clinical Pharmacokinetics. 51(10). 681–693.
8.
Tong, Gary, Junsheng Wang, Oleksandr Sverdlov, et al.. (2012). A contrast in safety, pharmacokinetics and pharmacodynamics across age groups after a single 50 mg oral dose of the γ‐secretase inhibitor avagacestat. British Journal of Clinical Pharmacology. 75(1). 136–145.
9.
Portelius, Erik, Kaj Blennow, Ulf Andréasson, et al.. (2011). O2‐01‐06: The Gamma Secretase Inhibitor, BMS‐708163 Increases Alpha Secretase Abeta Peptide Cleavage Fragments and Decreases the Gamma Secretase Abeta Peptide 1‐34 Fragment in Cerebrospinal Fluid. Alzheimer s & Dementia. 7(4S_Part_8).
10.
Piña-Crespo, Juan, Maria Talantova, Ileana Micu, et al.. (2010). Excitatory Glycine Responses of CNS Myelin Mediated by NR1/NR3 “NMDA” Receptor Subunits. Journal of Neuroscience. 30(34). 11501–11505.
11.
Tong, Gary, Shu‐Pang Huang, Randy Slemmon, et al.. (2010). P3‐298: The safety, tolerability, pharmacokinetics and pharmacodynamics of single doses of BMS‐708163 in young and elderly subjects. Alzheimer s & Dementia. 6(4S_Part_17).
12.
Sweetser, Seth, Michael Camilleri, Duane D. Burton, et al.. (2009). Do corticotropin releasing factor-1 receptors influence colonic transit and bowel function in women with irritable bowel syndrome?. American Journal of Physiology-Gastrointestinal and Liver Physiology. 296(6). G1299–G1306.
13.
Okamoto, Shu‐ichi, Mahmoud A. Pouladi, Maria Talantova, et al.. (2009). Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nature Medicine. 15(12). 1407–1413.
14.
Sweetser, Seth, Duane D. Burton, April Grudell, et al.. (2008). T1405 Effects of a Novel Corticotrophin Releasing Factor Receptor-1 Antagonist, BMS-562086, On Gastrointestinal and Colonic Transit and Bowel Habits in Patients with Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS). Gastroenterology. 134(4). A–548.
15.
Princen, Frédéric, Émilie Bard, Farah Sheikh, et al.. (2008). Deletion of Shp2 Tyrosine Phosphatase in Muscle Leads to Dilated Cardiomyopathy, Insulin Resistance, and Premature Death. Molecular and Cellular Biology. 29(2). 378–388.
16.
Takahashi, Hiroto, Yeonsook Shin, Wagner Zago, et al.. (2007). Hypoxia Enhances S-Nitrosylation-Mediated NMDA Receptor Inhibition via a Thiol Oxygen Sensor Motif. Neuron. 53(1). 53–64.
17.
Tu, Shichun, Yeonsook Shin, Wagner Zago, et al.. (2007). Takusan: A Large Gene Family that Regulates Synaptic Activity. Neuron. 55(1). 69–85.
18.
Tong, Gary, Hiroto Takahashi, Shichun Tu, et al.. (2007). Modulation of NMDA Receptor Properties and Synaptic Transmission by the NR3A Subunit in Mouse Hippocampal and Cerebrocortical Neurons. Journal of Neurophysiology. 99(1). 122–132.
19.
Lin, Peter Ping, Feng Li, Yun‐wu Zhang, et al.. (2006). Calnuc binds to Alzheimer’s β‐amyloid precursor protein and affects its biogenesis. Journal of Neurochemistry. 100(6). 1505–1514.
20.
Zhang, Xue, Yun‐wu Zhang, Shijie Liu, et al.. (2006). Tumor suppressor PTEN affects tau phosphorylation: deficiency in the phosphatase activity of PTEN increases aggregation of an FTDP-17 mutant Tau.. Molecular Neurodegeneration. 1(1). 7–7.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Nobuya Matsuoka Breakdown of academic impact, for papers by Per‐Göran Gillberg Breakdown of academic impact, for papers by Eleanor Drummond Breakdown of academic impact, for papers by Nicola Origlia Breakdown of academic impact, for papers by Francisco J. Gil‐Bea Breakdown of academic impact, for papers by Paul Ardayfio Breakdown of academic impact, for papers by Karen H. Gylys Breakdown of academic impact, for papers by Emma L. Jones Breakdown of academic impact, for papers by Hitoshi Tanimukai